Trial Profile

A Randomized, Double Blind, Placebo Controlled Study of the Effects of Etanercept in Children Presenting With Kawasaki Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etanercept (Primary) ; Aspirin; Immune globulin
Indications Mucocutaneous lymph node syndrome
Focus Therapeutic Use
Acronyms EATAK

Most Recent Events

13 Apr 2023 Status changed from active, no longer recruiting to completed.
01 Apr 2023 Results (n=40) evaluating the potential long-term benefit of etanercept for coronary disease patient group, published in the Cardiology in the Young
16 Apr 2018 Planned End Date changed from 1 Feb 2018 to 1 Aug 2018.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com